Brokerages Expect Wave Life Sciences Ltd (NASDAQ:WVE) to Announce -$1.48 Earnings Per Share

Wall Street brokerages expect that Wave Life Sciences Ltd (NASDAQ:WVE) will report ($1.48) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Wave Life Sciences’ earnings, with estimates ranging from ($1.81) to ($1.11). Wave Life Sciences posted earnings of ($1.29) per share in the same quarter last year, which would indicate a negative year over year growth rate of 14.7%. The business is scheduled to announce its next earnings results on Friday, March 6th.

According to Zacks, analysts expect that Wave Life Sciences will report full year earnings of ($5.54) per share for the current year, with EPS estimates ranging from ($5.87) to ($5.17). For the next financial year, analysts expect that the firm will post earnings of ($4.44) per share, with EPS estimates ranging from ($5.90) to ($3.32). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.34) by ($0.14). The firm had revenue of $2.93 million during the quarter, compared to analyst estimates of $6.30 million. Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%.

Several research analysts recently commented on the stock. Guggenheim began coverage on shares of Wave Life Sciences in a report on Friday, November 1st. They issued a “buy” rating and a $43.00 target price on the stock. Mizuho assumed coverage on Wave Life Sciences in a research report on Thursday, November 21st. They issued a “buy” rating and a $65.00 price target on the stock. ValuEngine upgraded Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 29th. BidaskClub upgraded Wave Life Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Finally, HC Wainwright set a $33.00 price objective on Wave Life Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $45.00.

NASDAQ:WVE opened at $34.23 on Friday. Wave Life Sciences has a 1 year low of $17.59 and a 1 year high of $50.98. The firm’s fifty day simple moving average is $26.70 and its 200 day simple moving average is $24.12. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.26.

In related news, Director Gregory L. Verdine sold 30,039 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.63, for a total transaction of $920,094.57. Following the completion of the transaction, the director now directly owns 36,009 shares in the company, valued at approximately $1,102,955.67. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 39.70% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC lifted its position in shares of Wave Life Sciences by 16.1% in the 2nd quarter. Janus Henderson Group PLC now owns 3,392,298 shares of the company’s stock worth $88,505,000 after acquiring an additional 470,402 shares during the period. Athanor Capital LP acquired a new stake in shares of Wave Life Sciences in the 2nd quarter valued at $566,000. Swiss National Bank boosted its stake in shares of Wave Life Sciences by 2.4% in the 2nd quarter. Swiss National Bank now owns 34,200 shares of the company’s stock valued at $892,000 after purchasing an additional 800 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Wave Life Sciences by 8.7% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 115,769 shares of the company’s stock worth $3,021,000 after purchasing an additional 9,273 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its holdings in shares of Wave Life Sciences by 93.3% in the 2nd quarter. Virtus ETF Advisers LLC now owns 10,387 shares of the company’s stock worth $271,000 after purchasing an additional 5,014 shares during the last quarter. Hedge funds and other institutional investors own 90.00% of the company’s stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Further Reading: What is a Call Option?

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.